Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
M.D. Anderson Cancer Center
Sun Yat-sen University
Northwestern University
Baptist Health South Florida
University of Iowa
Washington University School of Medicine
Stanford University
Massachusetts General Hospital
Medical College of Wisconsin
Emory University
Candel Therapeutics, Inc.
Meyer Children's Hospital IRCCS
Fifth Affiliated Hospital, Sun Yat-Sen University
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Children's Oncology Group
Radiation Therapy Oncology Group
Duke University
SCRI Development Innovations, LLC
Baylor College of Medicine
Duke University
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Huashan Hospital
University of Iowa
CytoVac A/S
People's Hospital of Guangxi Zhuang Autonomous Region
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Colorado, Denver
Duke University
Dartmouth-Hitchcock Medical Center
Dr. Negrin University Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University College, London
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Biotech Pharmaceutical Co., Ltd.
University College, London
University of Cincinnati
University of California, San Francisco
King Fahad Medical City
Merck Sharp & Dohme LLC
EMD Serono
Alliance for Clinical Trials in Oncology
University of Zurich